A new lipid nanoparticle could make mRNA vaccines more powerful and potentially lower the cost per vaccine dose.
Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 45.4% ...
Growing investments in mRNA vaccine and therapeutic platforms, along with regulatory acceleration, are fueling steady global demand for high-purity raw materials.Austin, Nov. 04, 2025 (GLOBE NEWSWIRE) ...
A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...
Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in ...
In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created COVID ...
Maximize capping efficiency and minimize double-stranded RNA ("dsRNA") in the manufacturing of self-amplifying mRNA SAN DIEGO ...
STONY BROOK, NY / ACCESSWIRE / November 9, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback